Genetic markers will help doctors find the best embryos to increase the success rate of in vitro fertilization (IVF) in just one procedure. However, the disadvantage of IVF is that if only one embryo is placed in the uterus, the doctor has no criteria to choose a healthy embryo and one that is free of genetic diseases. This has changed when doctors can now biopsy "embryo cells for DNA testing to provide information about the ability of this embryo to become a fetus."

Preimplantation genetic testing (PGT) is a technique used in reproductive medicine to identify genetic abnormalities in embryos (less commonly, polar bodies of eggs) created through in vitro fertilization..

Genetic diagnosis and testing before embryo transfer in infertility treatment is one of the necessary tasks, helping to improve the effectiveness of reproductive health care, supporting infertility treatment for families or limiting the risk of giving birth to children with genetic diseases.

Preimplantation genetic diagnosis (PGD) has been used since 1990 and has become one of the fastest growing techniques in assisted reproduction. The purpose of this embryo biopsy technique is to screen healthy embryos in couples who are at high risk of having a child with a genetic disorder.

PGT-A stands for preimplantation genetic testing for aneuploidy. It was previously called PGS (preimplantation genetic screening).

In IVF, selecting a good embryo to prepare for transfer plays a very important role. Especially in cases where there are many embryos. If the embryo has a good morphology, the doctor and the couple will usually expect the embryo to have good development potential.

Pre-implantation genetic testing for monogenic disease (PGT-M) is a genetic test performed on embryos to reduce the risk of pregnancy with a monogenic genetic abnormality in high-risk parents.